Targovax is developing a cancer immunotherapeutic technology with a targeted mechanism of action, making tumors visible to the immune system and educating the immune system to recognize and attack patient specific tumor cells. The technology is based on adenoviruses engineered to kill tumor cells primarily via activation of a systemic, patient-specific anti-tumor immune response. The lead clinical candidate is ONCOS-102.

This technology is designed to enhance immunotherapy by:

  • Strengthening response in known immunogenic tumors by enhancing already present T cell responses through powerful co-stimulation.
  • Expanding immunotherapy to less immunogenic tumor types by educating the immune system to recognize and attack tumors in patients with little or no pre-existing functional anti-tumor immune activity.

Within the Targovax portfolio are several viruses with different transgenes in its portolio. In addition, Targovax is developing new viruses with novel characteristics. The unique combination of our product development and manufacturing platforms provides us with an efficient environment to take new products into clinical development.